surmount-1 tirzepatide weight loss nondiabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial 𝐃𝐨𝐜, 𝐬𝐢𝐧𝐜𝐞 𝐦𝐲 𝐰𝐞𝐢𝐠𝐡𝐭 𝐢𝐬

The medication is administered as a once-weekly injection under the skin

Step 3: Prescription and delivery Once approved, your prescription goes to the compounding pharmacy

Glycine may help reduce injection site reactions and improve tolerability for some users

Your drug levels at trough will be lower than they were on your compressed schedule

21 December 2023

Add-on to metformin with or without SGLT2 inhibitor SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily